IE 11 is not supported. For an optimal experience visit our site on another browser.

Bavarian Nordic Has Signed Contract With Denmark and Another European NATO Country for the Delivery of IMVAMUNE(R) Smallpox Vaccine

/ Source: GlobeNewswire

KVISTGARD, Denmark, June 15, 2011 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (Copenhagen:BAVA) today announced that it has signed a contract with the Danish Defence for the delivery of the company's third generation smallpox vaccine, IMVAMUNE(R). Furthermore, Bavarian Nordic has signed a contract with another European NATO country for the delivery of IMVAMUNE(R).

The vaccines will be delivered in 2011. The size and value of the contracts are undisclosed.

Like the U.S. government, which has so far ordered 20 million doses of the vaccine, IMVAMUNE(R) will form part of these countries' bio-preparedness in the event of a smallpox outbreak due to e.g. an act of terrorism. Although IMVAMUNE(R) is an unlicensed vaccine, it has been made available for government purchase. Data from more than 10 years of research indicate that IMVAMUNE(R) has a favorable safety profile and is well tolerated, including in people who are not recommended to receive the traditional smallpox vaccines, such as people with weakened immune systems (e.g. people infected with HIV) or diagnosed with atopic dermatitis (skin allergies). 

The contracts do not affect the company's expectations for the 2011 full year results. 

Anders Hedegaard, President & CEO comments: "Although these are smaller orders, we believe they can be the launch pad for a long-term cooperation on building up a modern bio-preparedness in these countries. Just like the U.S., Canada and the other countries which have purchased our vaccine, these countries now recognize the excellent features of IMVAMUNE(R), which not only appears to be safer, but studies have also shown it has faster onset of protection than the old vaccines. We are continuously working to position IMVAMUNE(R) towards governments and national defences in other countries that have shown their interest in the vaccine."

CONTACT: Anders Hedegaard, President & CEO Phone +45 23 20 30 64